DE60335743D1 - Verbindungen und verfahren zur erhöhung der neurogenese - Google Patents

Verbindungen und verfahren zur erhöhung der neurogenese

Info

Publication number
DE60335743D1
DE60335743D1 DE60335743T DE60335743T DE60335743D1 DE 60335743 D1 DE60335743 D1 DE 60335743D1 DE 60335743 T DE60335743 T DE 60335743T DE 60335743 T DE60335743 T DE 60335743T DE 60335743 D1 DE60335743 D1 DE 60335743D1
Authority
DE
Germany
Prior art keywords
agents
neurogenesis
increasing
compounds
intracellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60335743T
Other languages
English (en)
Inventor
Goeran Bertilsson
Rikard Erlandsson
Jonas Frisen
Anders Haegerstrand
Jessica Heidrich
Kristina Hellstroem
Johan Haeggblad
Katarina Jansson
Jarkko Kortesmaa
Per Lindquist
Hanna Fraemme
Jacqueline Mcguire
Alex Mercer
Karl Nyberg
Amina Ossoinak
Cesare Patrone
Harriet Roennholm
Olof Zachrisson
Lilian Wikstroem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NeuroNova AB
Original Assignee
NeuroNova AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326612&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60335743(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by NeuroNova AB filed Critical NeuroNova AB
Application granted granted Critical
Publication of DE60335743D1 publication Critical patent/DE60335743D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
DE60335743T 2002-11-20 2003-11-20 Verbindungen und verfahren zur erhöhung der neurogenese Expired - Lifetime DE60335743D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42791202P 2002-11-20 2002-11-20
PCT/IB2003/005311 WO2004045592A2 (en) 2002-11-20 2003-11-20 Compounds and methods for increasing neurogenesis

Publications (1)

Publication Number Publication Date
DE60335743D1 true DE60335743D1 (de) 2011-02-24

Family

ID=32326612

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60335743T Expired - Lifetime DE60335743D1 (de) 2002-11-20 2003-11-20 Verbindungen und verfahren zur erhöhung der neurogenese

Country Status (14)

Country Link
US (1) US20050009847A1 (de)
EP (1) EP1583541B1 (de)
JP (2) JP5420813B2 (de)
AT (1) ATE494904T1 (de)
AU (1) AU2003280117B2 (de)
CA (1) CA2506850C (de)
CY (1) CY1111386T1 (de)
DE (1) DE60335743D1 (de)
DK (1) DK1583541T3 (de)
ES (1) ES2359720T3 (de)
HK (1) HK1091112A1 (de)
PT (1) PT1583541E (de)
SI (1) SI1583541T1 (de)
WO (1) WO2004045592A2 (de)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691145B2 (en) * 1999-10-22 2010-04-06 Facet Solutions, Inc. Prostheses, systems and methods for replacement of natural facet joints with artificial facet joint surfaces
EP1423509A2 (de) * 2001-08-30 2004-06-02 Stem Cell Therapeutics Inc. Differenzierung von neuralen stammzellen und therapeutische anwendung
EP1430114B1 (de) * 2001-09-14 2012-01-18 Stem Cell Therapeutics Inc. Prolaktin-induzierte zunahme an neuronalen stammzellen und dessen therapeutische anwendung
AR036402A1 (es) * 2001-09-18 2004-09-08 Stem Cell Therapeutics Inc Efecto de la hormona de crecimiento y de igf-1 sobre celulas madre neuronales.
AU2003250705A1 (en) * 2002-07-31 2004-02-16 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
FR2856595B1 (fr) * 2003-06-27 2008-05-30 Exonhit Therapeutics Sa Methodes et compositions pour le traitement de deficits cognitifs.
US20070111932A1 (en) * 2003-07-31 2007-05-17 Stem Cell Therapeutics Inc. Method of enhancing and/or inducing neuronal migration using erythropoietin
WO2005081619A2 (en) * 2003-11-20 2005-09-09 Neuronova Ab Compounds and methods for increasing neurogenesis
CA2556266A1 (en) * 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Use of luteinizing hormone (lh), and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
US8475764B2 (en) 2004-05-24 2013-07-02 Institut De Cardiologie De Montreal Labelled adrenomedullin derivatives and their use for imaging and therapy
EP1749026B1 (de) 2004-05-24 2011-11-23 Institut de Cardiologie de Montréal Markierte adrenomedullinderivate und deren verwendung zur bilddarstellung und therapie
EP1619251A1 (de) 2004-07-22 2006-01-25 Prosensa B.V. Ein mRNA Spleisvariant des Doublecortin-ähnlichen Kinasegens und dessen Anwendung in Krebsdiagnosis und Krebstherapie
AU2006204699B2 (en) * 2005-01-13 2012-04-26 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
US20090220587A1 (en) * 2005-02-01 2009-09-03 United State Army Liposomal drug delivery constructs targeted by lipid-conjugated peptide ligands
US7741431B2 (en) * 2005-02-01 2010-06-22 The United States Of America As Represented By The Secretary Of The Army Liposomes containing novel targeting and/or fusogenic peptides, preparations containing them and therapeutic use thereof
DE102005036094A1 (de) * 2005-08-01 2007-02-08 B.R.A.H.M.S Ag In vitro Verfahren zur Diagnose von neurodegenerativen Erkrankungen
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
US7534765B2 (en) * 2005-09-27 2009-05-19 Stem Cell Therapeutics Corp. Pregnancy-induced oligodendrocyte precursor cell proliferation regulated by prolactin
CA2625153A1 (en) * 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) * 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
JP5050195B2 (ja) * 2006-02-14 2012-10-17 国立大学法人 岡山大学 神経細胞分化誘導剤
JP5424291B2 (ja) * 2006-03-03 2014-02-26 独立行政法人国立循環器病研究センター 骨髄細胞の動員剤および動員方法
WO2007104035A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009149524A (ja) * 2006-03-16 2009-07-09 Kyushu Univ アルツハイマー病の予防・治療剤
KR20080106976A (ko) * 2006-03-17 2008-12-09 스템 셀 테라퓨틱스 코포레이션 신경 줄기 세포 증식제 및 신경 줄기 세포 분화제의 연속 투여 방법
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2377531A2 (de) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenese mittels Angiotensin-Modulation
US20090197823A1 (en) * 2006-05-09 2009-08-06 Braincells, Inc. Aliskiren modulation of neurogenesis
US7858611B2 (en) 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
KR100838013B1 (ko) * 2006-06-07 2008-06-12 제일약품주식회사 인간배아줄기세포로부터 단계적 선별법을 통해 고수율로신경전구세포, 신경세포 및 기능성 도파민신경세포를생성하는 방법
WO2008030651A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CA2663347A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. Ppar mediated modulation of neurogenesis
CA2672524C (en) * 2006-12-14 2016-08-23 Neuronova Ab Treatment of disease or injury of the nervous system using agents that decrease the activity of the melanocortin 4 receptor
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
US20080171750A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation Of Neurogenesis With Use of Modafinil
WO2008097861A2 (en) * 2007-02-02 2008-08-14 Braincells, Inc. MODULATION OF NEUROGENESIS WITH BIGUANIDES AND GSK3-ß AGENTS
WO2008138141A1 (en) * 2007-05-11 2008-11-20 Institut De Cardiologie De Montréal Labelled adrenomedullin derivatives and their use for imaging and therapy.
JP2010534653A (ja) * 2007-07-27 2010-11-11 イミューンリジェン バイオサイエンシズ，インク． サブスタンスｐ又はそのアナログを用いて、幹細胞の増殖又は分化を刺激するための方法及び組成物
WO2009033809A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
CA2699087A1 (en) * 2007-09-11 2009-04-16 Dorian Bevec Use of a peptide as a therapeutic agent
US20100197599A1 (en) * 2007-09-11 2010-08-05 Dorian Bevec Use of a peptide as a therapeutic agent
RU2010114024A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение гонадорелина в качестве терапевтического средства
FR2926464B1 (fr) * 2008-01-18 2012-01-20 Centre Nat Rech Scient Composes utilisables pour le traitement de douleurs neuropathiques
ES2375924T3 (es) * 2008-01-18 2012-03-07 Centre National De La Recherche Scientifique - Cnrs Agonistas beta-2 adrenérgicos para su utilización en el tratamiento de la alodinia neurop�?tica crónica.
WO2009123877A1 (en) * 2008-03-21 2009-10-08 Braincells, Inc. A method of treating a nervous system disorder by modulation of neurogenesis with mcc-257
JPWO2009136587A1 (ja) * 2008-05-08 2011-09-08 株式会社カネカ 抗疲労組成物
WO2010019450A2 (en) * 2008-08-09 2010-02-18 Nyles Bauer Synergizing active compounds for treating inflammation and other conditions
GB0815315D0 (en) * 2008-08-21 2008-09-24 Univ Leiden Organ protection
KR101820024B1 (ko) 2008-10-17 2018-01-18 사노피-아벤티스 도이칠란트 게엠베하 인슐린과 ｇｌｐ－1 효능제의 병용물
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2408460B1 (de) 2009-03-20 2018-09-26 HG&H Pharmaceuticals (Pty) Limited Sceletium extrakt und verwendungen davon
EP2408446B1 (de) 2009-03-20 2019-09-11 HG&H Pharmaceuticals (Pty) Limited Verwendung pharmazeutische zubereitungen enthaltend mesembrenon
JP5498571B2 (ja) 2009-04-30 2014-05-21 ミッドウェスタン ユニバーシティ センタキンを用いた新規の治療方法
MX2011012043A (es) * 2009-05-13 2012-03-29 Protein Delivery Solutions Llc Sistema farmaceutico para suministro transmembrana.
ES2534191T3 (es) 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
HUE037735T2 (hu) 2009-11-13 2018-09-28 Sanofi Aventis Deutschland DesPro36exendin-4(1-39)-Lys6-NH2-t és metionint tartalmazó gyógyszerkészítmény
EP2568999B1 (de) * 2010-05-11 2018-07-11 Mallinckrodt Ard Ip Limited Acth zur behandlung von amyotropher lateralsklerose
SG10201503032UA (en) * 2010-06-16 2015-06-29 Sigma Tau Ind Farmaceuti Acetyl-carnitine for use in a method for increasing neurogenesis in neural tissue
BR112013004756B1 (pt) 2010-08-30 2020-04-28 Sanofi Aventis Deutschland uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2
JP5946454B2 (ja) 2010-08-31 2016-07-06 バイオニュア ファーマ， エセ．エレ． ニューロトロフィン受容体のアゴニストおよび医薬としてのその使用
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AU2012276037A1 (en) * 2011-06-29 2014-02-13 Mayo Foundation For Medical Education And Research Small molecule CD38 inhibitors and methods of using same
RU2650616C2 (ru) 2011-08-29 2018-04-16 Санофи-Авентис Дойчланд Гмбх Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
US9193710B2 (en) 2011-08-29 2015-11-24 Sanford-Burnham Medical Research Institute Benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
CN104870009B (zh) 2012-12-21 2021-05-18 赛诺菲 官能化的毒蜥外泌肽-4衍生物
JP6928450B2 (ja) * 2013-07-08 2021-09-01 ミッドウェスタン ユニバーシティ エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物及び方法
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080154B1 (de) 2013-12-13 2018-02-07 Sanofi Duale glp-1/gip-rezeptoragonisten
EP3080152A1 (de) 2013-12-13 2016-10-19 Sanofi Nicht-acylierte exendin-4-peptidanaloga
EP3080149A1 (de) 2013-12-13 2016-10-19 Sanofi Duale glp-1-/glucagon-rezeptoragonisten
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
JP6970615B2 (ja) 2014-12-12 2021-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリングラルギン／リキシセナチド固定比処方
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
CA2987033C (en) * 2015-06-22 2023-11-28 Nestec S.A. Compositions and methods for enhancing neurogenesis in animals
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CN108884444A (zh) * 2016-03-31 2018-11-23 味之素株式会社 使神经分化能力增强的神经干细胞用培养基
WO2018074463A1 (ja) * 2016-10-17 2018-04-26 国立大学法人 熊本大学 ｃＡＭＰの増加をメカニズムとする有機酸血症における神経障害治療薬剤
KR102026156B1 (ko) * 2018-03-16 2019-09-27 (주)메디노 신경줄기세포의 신경분화 방법
WO2019246398A1 (en) * 2018-06-21 2019-12-26 Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno Disease modifying methods for treating neurodegenerative diseases using nootropic agents
WO2021011878A1 (en) * 2019-07-18 2021-01-21 Venturis Therapeutics, Inc. Method of treating parkinson's disease
JP2022104448A (ja) * 2020-12-28 2022-07-08 純一 今村 認知症治療薬
CN113121641B (zh) * 2021-03-11 2022-11-01 武汉英纳氏药业有限公司 一类多功能多肽及其在医药领域的应用
CN115869459B (zh) * 2021-09-27 2024-06-21 广州图微科创生物科技有限公司 促伤口愈合的多肽水凝胶及其制备方法与应用
CN115887619B (zh) * 2021-09-30 2024-03-26 四川大学 中脑星形胶质细胞源性神经营养因子的用途及药物组合物
WO2024030977A2 (en) * 2022-08-03 2024-02-08 Sightstream Biotherapeutics, Inc. Novel melanocortin analogs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016437A1 (en) * 1993-12-17 1995-06-22 Micro-Pak, Inc. Method of transmitting a biologically active material to a cell
US5968829A (en) * 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6268352B1 (en) * 1998-09-02 2001-07-31 The Regents Of The University Of California Promoters of neural regeneration
US6284539B1 (en) * 1998-10-09 2001-09-04 Neuralstem Biopharmaceuticals, Ltd. Method for generating dopaminergic cells derived from neural precursors
US6610540B1 (en) * 1998-11-18 2003-08-26 California Institute Of Technology Low oxygen culturing of central nervous system progenitor cells
AU5945301A (en) * 2000-05-05 2001-11-20 Res Foundation Of City Univers Methods for stimulating nervous system regeneration and repair by regulating arginase i and polyamine synthesis
WO2002083877A1 (en) * 2001-04-11 2002-10-24 Stem Cell Therapeutics Inc. Production of tyrosine hydroxylase positive neurons
US20040247571A1 (en) * 2001-04-23 2004-12-09 Xia Meijer Neural cells expressing tyrosine hydroxylase

Also Published As

Publication number Publication date
JP5420813B2 (ja) 2014-02-19
WO2004045592A3 (en) 2004-11-04
EP1583541A2 (de) 2005-10-12
CA2506850A1 (en) 2004-06-03
AU2003280117A1 (en) 2004-06-15
US20050009847A1 (en) 2005-01-13
CY1111386T1 (el) 2015-08-05
AU2003280117B2 (en) 2009-09-10
EP1583541B1 (de) 2011-01-12
ES2359720T3 (es) 2011-05-26
JP5421194B2 (ja) 2014-02-19
ATE494904T1 (de) 2011-01-15
WO2004045592A2 (en) 2004-06-03
CA2506850C (en) 2014-05-13
JP2006514630A (ja) 2006-05-11
HK1091112A1 (en) 2007-01-12
JP2010195841A (ja) 2010-09-09
SI1583541T1 (sl) 2011-08-31
DK1583541T3 (da) 2011-04-11
PT1583541E (pt) 2011-04-06

Similar Documents

Publication Publication Date Title
DE60335743D1 (de) Verbindungen und verfahren zur erhöhung der neurogenese
ATE414089T1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
EA200500169A1 (ru) Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение
EA200500856A1 (ru) Новые химические соединения
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE354563T1 (de) Sulfonderivate zur hemmung von gamma-secretase
ATE490788T1 (de) Antivirale phosphonate analoge
CL2004000647A1 (es) Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am
UY27774A1 (es) Inhibidores de metaloproteinas de triaril-oxi-aril-espiropirimidina-2,4,6-triona
EA200300929A1 (ru) Новые лекарственные композиции на основе антихолинергических средств и ингибиторов pde-iv
DE60330161D1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
ATE338036T1 (de) Zur behandlung hyperproliferativer erkrankungen geeignete benzofuran- und benzothiophenderivate
ATE534649T1 (de) Imidazothiazole und imidazoxazolderivative als inhibitoren von p38
ATE371454T1 (de) Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie
ATE363474T1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
ATE423110T1 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
DE602005021766D1 (de) Verfahren zur behandlung von atherosklerose
DE60334839D1 (de) Hybridpolymerase-verfahren und -zusammensetzungen
ATE410235T1 (de) Behandlung von ballastwasser
ATE416756T1 (de) Methoden zur verwendung von lamellaren körpern für therapeutische zwecke
DE60323533D1 (de) Methode zur stimulierung von haarwuchs auf der basis von benzopyranen
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE60213365D1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen